Active substance
Carbachol
- US FDA 3
- Health Canada 1
- WHO EML 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MIOSTAT OPHTHALMIC LIQ 0.01% | 00042544 | 0.01 % | SOLUTION · INTRAOCULAR | ALCON CANADA INC |
WHO WHO Model List of Essential Medicines (2025)
- 21.4. Ophthalmological preparations > Miotics and antiglaucoma medicines · core
Therapeutic equivalent to pilocarpine for Acute angle closure with pupillary block; Therapeutic equivalent to pilocarpine for Ocular hypertension; Therapeutic equivalent to pilocarpine for Primary open-angle glaucoma
Safety signals and safety-related labeling changes
- US FDA 21 Jan 2016 MIOSTAT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.